Related Experiment Video
Updated: Jul 5, 2025

Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes
Published on: January 12, 2024
Development of a PROTAC Targeting Chk1
Sandipan Roy Chowdhury1, Patrick Chuong1, Victoria E Mgbemena2
1Department of Pharmacological and Pharmaceutical Sciences, University of Houston College of Pharmacy, Health 2, 4349 Martin Luther King Boulevard, Houston, Texas, 77204.
Abstract:
A series of Chk1 degraders were designed and synthesized. The degraders were developed through the conjugation of a promiscuous kinase binder and thalidomide. One of the degraders PROTAC-2 was able to decrease Chk1 levels in a concentration-dependent manner in A375 cells. The developed probes can be useful for the development of selective and more potent Chk1 degraders.
More Related Videos
05:33High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
Published on: November 9, 2020
09:13Author Spotlight: Identifying Compensatory Pathways in Malaria Parasites Containing Hypomorphic Allele of Essential Protein Kinases
Published on: November 22, 2024
Related Concept Videos
DNA Damage can Stall the Cell Cycle
Targeted Cancer Therapies
There are several types of targeted therapies against...
PI3K/mTOR/AKT Signaling Pathway
Restarting Stalled Replication Forks
MAPK Signaling Cascades
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...